InVivo touts 2 patient recoveries in Inspire trial

InVivo Therapeutics (NSDQ:NVIV) said today that 2 patients in the Inspire trial of its neuro-spinal scaffold have shown significant improvements in motor recovery assessments. The Cambridge, Mass.-based company’s neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. InVivo said that the 2 patients improved from sensory incomplete AIS B spinal cord injuries to motor incomplete AIS C injuries during their most recent assessments as part of the trial. One of the improved patients was enrolled last May, and converted from complete AIS A SCI to incomplete AIS B SCI at 3 months, then was assessed to have improved to incomplete AIS C SCI at their 12-month follow-up. “The patient’s continued improvement at the 1 year exam is encouraging. Return of sacral motor function may be related to improvements in bowel and bladder function that can have an appreciable impact on a patient’s quality of life. We look forward to monitoring this patient’s recovery and hope for continued progress,” principal investigator Dr. Stuart Lee, who assessed the 1st patient, said in a press release. The 2nd improved patient was enrolled in June 2015 and converted from complete AIS A SCI to incomplete AIS B SCI at a 1-month exam that July. At 24 months, the patient was assessed to be AIS C with the ability to contract 2 muscles in 1 leg. “This patient moved from AIS A to AIS B shortly afte...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Spinal InVivo Therapeutics Source Type: news